Morpholine → HCID 44545155, compound

HRID 2093399Notes

Reaction equation

HRID 2093399 reaction equation
C(OC([NH:8][C:9]1[N:14]=[CH:13][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][CH2:25][C:26]([OH:28])=O)=[C:17]([N:29]3[CH2:34][CH2:33][O:32][CH2:31][CH2:30]3)[N:16]=2)=[CH:11][N:10]=1)=O)(C)(C)C.[NH:35]1[CH2:40][CH2:39][O:38][CH2:37][CH2:36]1>>[NH2:8][C:9]1[N:10]=[CH:11][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][CH2:25][C:26]([N:35]3[CH2:40][CH2:39][O:38][CH2:37][CH2:36]3)=[O:28])=[C:17]([N:29]3[CH2:30][CH2:31][O:32][CH2:33][CH2:34]3)[N:16]=2)=[CH:13][N:14]=1

Participants

3

Reactant 2

HCID 8083MorpholineHCID 66909826HCID 66909826, compound

Product 1

HCID 44545155HCID 44545155, compound

Procedure

3-(2-(2-(Tert-butoxycarbonylamino)pyrimidin-5-yl)-6-morpholino-9H-purin-9-yl)propanoic acid (50 mg) was reacted with morpholine via General Procedure F followed by Boc deprotection via General Procedure E to give 24.9 mg 113 as white solid following reverse phase purification. MS (Q1) 440.2 (M)+

Workup

  1. customto give
  2. custom24.9 mg 113 as white solid following reverse phase purification

Sources & evidence

ORD record
ord-867f6ef9101e4fccbcedd1ada848cc0a
Source dataset
uspto-grants-2013_05
Patent number
US08445487B2

Reaction notes

Loading…